The Absence of Thyroid Disease in an Australian Hepatitis C Cohort Treated With Triple Combination Therapy: A Paradigm Shift |
| |
| Institution: | 1. From the Pathology North Hunter and University of Newcastle, New South Wales, Australia;2. Hepatitis C Service, Gastroenterology Department, John Hunter Hospital and University of Newcastle, New South Wales, Australia.;1. From the University of Miami Miller School of Medicine, Miami;2. Florida, Lahey Clinic Northshore, Peabody, Massachusetts and Tufts School of Medicine, Boston, Massachusetts;3. Division of Endocrinology, State University of New York at Buffalo, Buffalo, New York;4. Division of Endocrinology and Metabolism, Texas Tech University Health Sciences Center- Permian Basin Campus, Odessa, Texas;5. Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, Ohio;6. Molecular & Cellular Biology, Baylor College of Medicine Diabetes & Endocrinology, Baylor St. Luke''s Medical Center, Houston, Texas.;1. Department of Biomedical Engineering, Duke University, Durham, North Carolina, USA;2. Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA;3. Department of Orthopedic Surgery, Duke University Medical Center, Durham, North Carolina, USA;1. From the Department of Nephrology, Chinese Academy of Medical Sciences, Beijing, China;2. Department of Endocrinology & Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.;1. From the Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas;2. Division of Pediatric Endocrinology, Department of Pediatrics, University of Alabama School of Medicine, Birmingham, Alabama;3. Department of Epidemiology in the School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama;4. Division of Pediatric Surgery, Department of Surgery, University of Alabama School of Medicine, Birmingham, Alabama;5. School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. |
| |
| Abstract: | Objective: To assess the prevalence of thyroid disease in triple combination therapy with interferon (IFN)-α, ribavirin (RBV), and protease inhibitors (boceprevir and telaprevir) for the treatment of chronic hepatitis C virus (HCV) infection in an Australian hepatitis C cohort. Also, to compare with those who received dual RBV and IFN in the past.Methods: A preliminary, retrospective, and nested case control study of thyroid disease in patients who underwent triple combination therapy for chronic HCV infection compared with dual therapy at a major tertiary referral hospital center. Fifty-nine patients were treated with such therapy at the Hunter New England Area Hepatitis C Treatment Center. Of these, 38 were treated with boceprevir and 21 with telaprevir. All had genotype 1 HCV infection. The main outcome measures included (1) the prevalence of thyroid disease (TD), including hyperthyroidism and hypothyroidism, and (2) thyroid outcome comparison with patients who had received dual therapy.Results: There was no case of TD detected for the entire duration of therapy with triple anti-HCV therapy. There was a significant absence of TD in the protease inhibitor–treated group.Conclusion: No case of TD was detected during the treatment of HCV patients with protease inhibitor–based triple therapy. The reasons for this are unclear. Larger studies are necessary to confirm this finding.Abbreviations: CV = coefficient of variation fT3 = free triiodothyronine fT4 = free thyroxine HCV = hepatitis C virus IFN-α = interferon-alpha PI = protease inhibitor RBV = ribavirin TD = thyroid disease TSH = thyroid-stimulating hormone TTX = thyrotoxicosis |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
